Page 99 - 南京医科大学自然版

第44卷第11期 南京医科大学学报（自然科学版）
2024年11月 Journal of Nanjing Medical University（Natural Sciences） ·1565 ·

·临床研究·

替雷利珠单抗联合化疗一线治疗局部晚期或转移性肺鳞癌的

真实世界研究

乔晓娟，常丽娟，都 兰，高 萌，邢 舴，呼 群 *

内蒙古医科大学附属医院肿瘤内科，内蒙古 呼和浩特 010050

［摘 要］ 目的：评估替雷利珠单抗联合化疗一线治疗局部晚期/转移性肺鳞癌的疗效及安全性。方法：收集 2021 年 1 月—
2023年12月内蒙古医科大学附属医院就诊的肺鳞癌患者109例，其中替雷利珠单抗联合化疗组66例，化疗组43例，比较两组
患者的客观缓解率（objective response rate，ORR）、无进展生存期（progression free survival，PFS）、总生存期（overall survival，OS）
和治疗相关不良事件（treatment⁃related adverse event，TRAE）的发生率。结果：中位随访时间20.2个月，替雷利珠单抗联合化疗
组的ORR明显高于化疗组（75.8% vs. 51.2% ）、中位PFS明显延长（17.3个月 vs. 9.3个月），替雷利珠单抗联合化疗组中位OS未
达到，但死亡风险较化疗组（19.3个月）显著降低（HR=0.38，95%CI：0.19~0.68，P=0.002）。两组任意级别和3级及以上TRAE发
生率相似，替雷利珠单抗联合化疗组免疫相关不良事件（immune⁃related adverse events，irAE）发生率为28.8%，其中3级及以上
irAE仅1例（1.5%）发生免疫相关性肺炎。结论：一线替雷利珠单抗联合化疗显著提高局部晚期/转移性肺鳞癌的疗效，且总体
不良反应程度可控。
［关键词］ 替雷利珠单抗；局部晚期/转移性肺鳞癌；一线治疗；临床疗效；安全性
［中图分类号］ R734.2 ［文献标志码］ A ［文章编号］ 1007⁃4368（2024）11⁃1565⁃08
doi：10.7655/NYDXBNSN240588

A real⁃world study of tislelizumab combined with chemotherapy as first⁃line treatment for

locally advanced or metastatic squamous non⁃small⁃cell lung cancer
QIAO Xiaojuan，CHANG Lijuan，DU Lan，GAO Meng，XING Ze，HU Qun *
Department of Medical Oncology of the Affiliated Hospital of Inner Mongolia Medical University，Hohhot 010050，
China

［Abstract］ Objective：To evaluate the efficacy and safety of tislelizumab combined with chemotherapy as first⁃line treatment for
locally advanced or metastatic squamous non⁃small⁃cell lung cancer in the real⁃world. Methods：A total of 109 patients with lung
squamous cell carcinoma were included in the Affiliated Hospital of Inner Mongolia Medical University from January 2021 to
December 2023，of whom 66 patients in the tislelizumab combined with chemotherapy group and 43 patients in the chemotherapy
group. The objective response rate（ORR），progression⁃free survival（PFS），overall survival（OS）and the incidence of treatment⁃related
adverse events（TRAEs）of the two groups were evaluated. Results：At a median follow⁃up of 20.2 months，the ORR of the tislelizumab
combined with chemotherapy group was significantly higher than that of the chemotherapy group（75.8% vs. 51.2%）. The median PFS
prolonged significantly in the tislelizumab combined with chemotherapy group compared to the chemotherapy group（17.3 months vs.
9.3 months）. OS data were not reached in the tislelizumab combined with chemotherapy group，which was significantly longer than the
chemotherapy group（19.3 months，HR=0.38，95%CI：0.19-0.68，P=0.002）. The incidence of overall TRAEs and TRAEs above grade
3 in the two groups was similar. The incidence of immune⁃related adverse events（irAEs）in the tislelizumab combined chemotherapy
group was 28.8%，including one case（1.5%）of grade 3 and above immune⁃associated pneumonia. Conclusion：Tislelizumab combined

［基金项目］ 内蒙古自治区高等学校青年科技英才（NJYT22011）；内蒙古自治区自然科学基金（2021MS08153）；内蒙古自治区
高等学校科学研究项目（NJZY21596）；内蒙古医科大学科技百万工程联合项目［YKD2020KJBW（LH）039］；内蒙古自治区卫生
健康科技计划项目（202201295）
∗
通信作者（Corresponding author），E⁃mail：3676514930@qq.com